CHI3L1 and Alzheimer disease: Combinations of synaptic degeneration markers (e.g., neurogranin, synaptosomal-associated protein 25, and VILIP-1) with the inflammation marker YKL-40 revealed a remarkable and differential longitudinal change across the clinical spectrum of AD patients9.